trending Market Intelligence /marketintelligence/en/news-insights/trending/EMhtdwc91c5SUaa-EFgfIQ2 content esgSubNav
In This List

MaxCyte closes £20M placing

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


MaxCyte closes £20M placing

MaxCyte Inc. closed a share placement to raise about £20 million in gross proceeds for its CARMA platform.

The company issued 7,275,000 shares at £2.75 apiece with Panmure Gordon acting as the financial adviser, nominated adviser and broker to the company.

Completion of the placement is subject to shareholder approval.

The CARMA platform is meant to help the company develop treatments for ovarian cancer and acute myeloid leukemia, a type of blood cancer. It will also be used to develop treatments for other indications.